Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; supplies propagated vegetables and ornamental plants; and distributes and sells hemp-derived cannabidiol (CBD) products. The company also cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, dried flowers, vapes, dried milled strains, edibles, concentrates, and strain specific cannabis oils and extracts; and provides patient counseling and outreach services. Its adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc.

Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -36.36%. A quarter ago, it was expected that this company would post earnings of $0.04 per share when it actually produced earnings of $0.06, delivering a surprise of 50%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Aurora Cannabis, which belongs to the Zacks Medical - Products industry, posted revenues of $63.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.65%. This compares to year-ago revenues of $49.98 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Aurora Cannabis shares have added about 38.4% since the beginning of the year versus the S&P 500's gain of 1.7%.
What's Next for Aurora Cannabis?
While Aurora Cannabis has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Aurora Cannabis: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.17 on $69.13 million in revenues for the coming quarter and $0.44 on $268.33 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Abbott (ABT), has yet to report results for the quarter ended June 2025.
This maker of infant formula, medical devices and drugs is expected to post quarterly earnings of $1.25 per share in its upcoming report, which represents a year-over-year change of +9.7%. The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level.
Abbott's revenues are expected to be $11.05 billion, up 6.5% from the year-ago quarter.
Should You Invest in Aurora Cannabis Inc. (ACB)?
Before you invest in Aurora Cannabis Inc. (ACB), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Aurora Cannabis Inc. (ACB) Misses Q4 Earnings Estimates

(RTTNews) - Aurora Cannabis Inc. (ACB, ACB.TO), a Canadian medical cannabis company, reported Wednesday narrower net loss in its fourth quarter, and adjusted EBITDA surged from last year with higher revenues.
In the pre-market activity on the Nasdaq, Aurora shares were losing around 10.5 percent to trade at $5.26.
Net loss from continuing operations was $17.23 million, compared to a net loss of $20.327 million for the prior year period.
Adjusted EBITDA increased 619 percent to $16.68 million from $2.32 million a year ago. Consolidated adjusted gross margin before fair value adjustments was 62 percent, compared to 50 percent in the prior year period.
Total net revenue was $90.5 million, 34 percent higher than $67.4 million in the prior year period.
The growth was mainly due to 48 percent increase in global medical cannabis business and 32 percent growth in plant propagation business. These were slightly offset by lower quarterly revenue in consumer cannabis business.
The increase in medical cannabis net revenue was primarily due to higher sales to Australia, Germany, Poland, and the UK, as well as increased revenue in Canada to insurance covered and self-paying patients.
Aurora's consumer cannabis net revenue fell 20 percent.
Looking ahead for the first quarter, the company expects continued strong global cannabis revenue driven by improved performance in Canadian medical, comparable performance in consumer, offset by temporary declines in some of international markets.
Global cannabis are expected to be slightly lower sequentially.
The company expects positive adjusted EBITDA to continue, with a decline versus sequential fourth quarter, due to lower revenue contributions from the higher margin international markets.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Aurora Cannabis Q4 Loss Narrows, Adj.EBITDA Surges; Sees Sequentially Weak Demand In Q1; Stock Drops

The following companies are expected to report earnings prior to market open on 06/18/2025. Visit our Earnings Calendar for a full list of expected earnings releases.
Korn Ferry (KFY)is reporting for the quarter ending April 30, 2025. The staffing company's consensus earnings per share forecast from the 2 analysts that follow the stock is $1.25. This value represents a 0.79% decrease compared to the same quarter last year. In the past year KFY has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2025 Price to Earnings ratio for KFY is 14.00 vs. an industry ratio of 13.70, implying that they will have a higher earnings growth than their competitors in the same industry.
GMS Inc. (GMS)is reporting for the quarter ending April 30, 2025. The building company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.15. This value represents a 40.41% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2025 Price to Earnings ratio for GMS is 12.67 vs. an industry ratio of 20.80.
Aurora Cannabis Inc. (ACB)is reporting for the quarter ending March 31, 2025. The medical products company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.11. This value represents a no change for the same quarter last year. In the past year ACB has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 50%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for ACB is 13.37 vs. an industry ratio of 19.50.
Euroseas Ltd. (ESEA)is reporting for the quarter ending March 31, 2025. The shipping company's consensus earnings per share forecast from the 1 analyst that follows the stock is $3.35. This value represents a 25.94% increase compared to the same quarter last year. Zacks Investment Research reports that the 2025 Price to Earnings ratio for ESEA is 3.07 vs. an industry ratio of 13.80.
LiveOne, Inc. (LVO)is reporting for the quarter ending March 31, 2025. The audio video production company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.05. This value represents a 66.67% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2025 Price to Earnings ratio for LVO is -8.64 vs. an industry ratio of 10.00.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Earnings Report for June 18, 2025 : KFY, GMS, ACB, ESEA, LVO

High Tide Inc. (HITI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced a loss of $0.02, delivering a surprise of -100%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
High Tide, which belongs to the Zacks Medical - Products industry, posted revenues of $96.94 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 0.22%. This compares to year-ago revenues of $91.6 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
High Tide shares have lost about 26.2% since the beginning of the year versus the S&P 500's gain of 1.6%.
What's Next for High Tide?
While High Tide has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for High Tide: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.02 on $102.27 million in revenues for the coming quarter and -$0.07 on $404.52 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Aurora Cannabis Inc. (ACB), another stock in the same industry, has yet to report results for the quarter ended March 2025. The results are expected to be released on June 18.
This company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Aurora Cannabis Inc.'s revenues are expected to be $62.04 million, up 24.1% from the year-ago quarter.
Should You Invest in High Tide Inc. (HITI)?
Before you invest in High Tide Inc. (HITI), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
High Tide Inc. (HITI) : Free Stock Analysis Report
Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

High Tide Inc. (HITI) Reports Q2 Loss, Tops Revenue Estimates

Agilent Technologies (A) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.22 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 3.97%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.27 per share when it actually produced earnings of $1.31, delivering a surprise of 3.15%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Agilent, which belongs to the Zacks Medical - Products industry, posted revenues of $1.67 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 2.64%. This compares to year-ago revenues of $1.57 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Agilent shares have lost about 17.2% since the beginning of the year versus the S&P 500's gain of 0.7%.
What's Next for Agilent?
While Agilent has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Agilent: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.40 on $1.65 billion in revenues for the coming quarter and $5.54 on $6.73 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Aurora Cannabis Inc. (ACB), is yet to report results for the quarter ended March 2025.
This company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Aurora Cannabis Inc.'s revenues are expected to be $62.4 million, up 24.8% from the year-ago quarter.
Should You Invest in Agilent Technologies, Inc. (A)?
Before you invest in Agilent Technologies, Inc. (A), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agilent Technologies, Inc. (A) : Free Stock Analysis Report
Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Agilent Technologies (A) Q2 Earnings and Revenues Top Estimates

The year is a more than a month old, but Aurora Cannabis (NASDAQ: ACB) is already one of the hottest stocks to own in 2025. As of Feb. 11, the pot stock has soared more than 50% since the year began -- and that rally began only a few days ago.
Shares of Aurora got a big boost after the company posted its latest earnings numbers showing a strong profit. Could this be a turning point for Aurora after years of disappointment? Has the stock finally become a good buy?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Aurora's sales take off in Q3
On Feb. 5, Aurora Cannabis reported its fiscal third-quarter results for the period ended Dec. 31. The cannabis company reported impressive year-over-year growth, with sales rising by 37% to 88.2 million Canadian dollars ($61.7 million). This is an acceleration from the previous quarter, when its sales growth rate was 29%.
This is great news for a company that has struggled to generate much growth. In its home Canadian market, competition is fierce. Not only are margins extremely barrow, but it's also difficult to increase market share due to heavy restrictions on marketing and an abundance of cannabis producers.
To expand, Aurora has been focusing on selling medical marijuana products internationally, where it can sell at higher prices and produce better margins for the business. It was the international medical market that generated solid growth last quarter for Aurora, more than doubling from CA$19.2 million to CA$40.9 million. As that happened, the company's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) also rose significantly, from CA$5.5 million a year ago to CA$23.1 million this past quarter.
The company still faces risks, however
Aurora's results were encouraging, but that doesn't necessarily mean it's going to be smooth sailing in the future. The company's earnings numbers were strong last quarter, and Aurora posted a profit of CA$31.3 million compared with a net loss of CA$18.1 million a year earlier. However, that profit was heavily boosted by gains on its biological assets (that added CA$31.6 million to gross profit).
Earnings numbers for cannabis companies can fluctuate significantly and the company is going in the right direction. The big question is whether it can remain in the black as it continues to expand and without big one-time gains boosting the bottom line in the future.
Although the business had a good deal of growth last quarter, cannabis investors have seen this situation play out in the past, where new market opportunities lead to surging sales initially, only to slow drastically later on. As other Canadian cannabis companies see the growth Aurora is generating internationally, it may only be a matter of time before it faces more competition in those markets as well.
Aurora's business is showing some signs of progress, and it has come a long way over the years in becoming less dependent on the Canadian consumer cannabis market. However, whether investors decide to take a chance on the stock will ultimately come down to their risk tolerance.
Is Aurora Cannabis stock finally worth taking a chance on?
During the past five years, Aurora shares have plummeted 97% in value. The business does look better, and it's arguably a safer investment than it was five years ago. But that isn't saying much, given how badly it has performed during that stretch.
This is a highly volatile stock which has headed almost exclusively in the wrong direction. The danger is that although it's doing well now, it could take just one bad quarter or negative development in the cannabis industry to undo this recent rally. The shares could be a good option if you're a contrarian investor with a high risk tolerance. But for the vast majority of investors, this is still a stock that you'll likely be better off simply watching rather than buying.
Should you invest $1,000 in Aurora Cannabis right now?
Before you buy stock in Aurora Cannabis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Aurora Cannabis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $818,587!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of February 7, 2025
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Aurora Cannabis Skyrockets After Earnings: Should You Buy Into the Rally?

Aurora Cannabis (ACB) Q2 2025 Earnings Call Transcript

Wednesday, November 6, 2024
With the 2024 election behind us, stock markets are rallying higher across the board. Unlike the last time Donald Trump was elected President, when markets were unsure which direction to take equities initially, the Dow is currently +1300 points, the S&P 500 +132, the Nasdaq +361 and the small-cap Russell 2000 +141 points.
Bond yields are also rising. Not only does shedding uncertainty send markets higher, but inflationary measures promised by the Trump campaign to levy tariffs on imports from all over the world will keep prices high. The 10-year yield is +4.437% right now, with the 2-year at +4.268%.
Bitcoin is also at a new all-time high of $75K, which has helped stocks like Coinbase COIN surge +12% this morning, with Bitcoin-related ETFs like Ark 21Shares Bitcoin ARKB up +6%. The Trump administration is likely to be ver favorable of a deregulated cryptocurrency market.
Tesla TSLA shares are also +12% this morning, which can be seen as a play on Elon Musk, who may have an important role in Trump’s new government. It would stand to reason that all of Musk’s businesses would do well with their CEO in a position of government power, and Tesla is currently his only publicly traded company.
Also on the ballot yesterday in a number of states was the vote on whether to legalize marijuana. While Florida, North and South Dakota all rejected the proposal, it did pass in Dallas, TX and in the state of Nebraska. Aurora Cannabis ACB also posted a +118% earnings surprise this morning, but shares are down -5% early in this otherwise roaring hot market.
Q3 Earnings Season Rolls Along
We saw Toyota TM post an earnings miss this morning, which may cause it to lose its Zacks Rank #1 (Strong Buy) status in the coming days. After the close, we’ll get results from Qualcomm QCOM, Trip Advisor TRIP and Gilead GILD.
Check out the updated Zacks Earnings Calendar here.
Questions or comments about this article and/or author? Click here>>
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report
Toyota Motor Corporation (TM) : Free Stock Analysis Report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
Tesla, Inc. (TSLA) : Free Stock Analysis Report
TripAdvisor, Inc. (TRIP) : Free Stock Analysis Report
Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report
Coinbase Global, Inc. (COIN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Markets Surge on Historic Trump Victory

The global cannabis market stands on the cusp of a remarkable period of growth. Industry projections suggest it could grow from $57 billion in 2023 to $444 billion by 2030. This potential 7.7-fold increase over seven years translates to a compound annual growth rate of 34%, dwarfing the growth rates of many traditional industries.
Against this backdrop of industrywide potential, Canadian marijuana titan Aurora Cannabis (NASDAQ: ACB) has emerged as an unexpected bright spot in 2024. While most of its Canadian counterparts have wilted this year, Aurora's shares have blossomed with a 13% gain year to date. This performance starkly contrasts with industry peers Canopy Growth Corp. and Tilray Brands, which have seen their stocks wither by 18.5% and 28.2%, respectively.
Aurora's resilience in a challenging market for marijuana stocks raises an intriguing question for speculative growth investors: Is Aurora Cannabis stock still ripe for the picking after its strong performance over the first three quarters of 2024? Let's dig deeper to unearth the answer.
Medical cannabis: A high-margin focus
Aurora Cannabis has carved out its niche primarily in the medical cannabis market. This strategic focus appears to be bearing fruit. In the first quarter of FY 2025, Aurora reported record global medical cannabis net revenue of $47.2 million Canadian dollars, marking a 13% increase from the same period a year ago.
The medical cannabis segment offers higher margins, compared to its recreational counterpart. To wit, Aurora's adjusted gross margins for medical cannabis have consistently hit or exceeded the company's 60% target in recent quarters, reaching a healthy 69% in Q1. This emphasis on high-margin medical sales could be a sturdy foundation for Aurora's future growth and profitability.
Financial health improving
Aurora Cannabis has made significant strides in improving its financial position. The company achieved positive free cash flow of CA$6.5 million in Q1 FY 2025, a milestone Wall Street wasn't expecting until at least calendar year 2026. This achievement is particularly noteworthy given the company's history of cash burn and shareholder dilution.
Aurora has also worked to strengthen its balance sheet. As of the close of Q1 FY 2025, Aurora had approximately CA$182 million in cash and cash equivalents. This cash position provides the company with financial flexibility as it navigates the evolving cannabis market.
Global expansion and market potential
Aurora Cannabis has established a presence in key international markets, including Germany, Australia, and the United Kingdom. Germany recently became the largest European Union (E.U.) country to legalize cannabis for recreational use. However, the initial phase of this legalization focuses on personal possession and cultivation, along with non-profit "cannabis clubs" for distribution, rather than commercial sales.
This structure limits immediate opportunities for large-scale commercial operators like Aurora. Despite these current restrictions in Germany, Aurora's strong position in the country's medical cannabis market may offer significant advantages as regulations evolve. This international footprint could prove valuable as the global cannabis market continues to develop and grow.
Challenges remain
Aurora Cannabis still faces significant challenges despite these positive developments. The company operates in a highly regulated industry with ongoing legal uncertainties in multiple key geographies. Competition from both legal and illicit sources remains fierce. The Canadian market continues to be burdened by high excise taxes and costly regulations.
Perhaps most importantly for stock investors, Aurora has a history of diluting shareholders to raise capital. The company has more than doubled its outstanding share count in the past three years. The recent positive free-cash-flow news is encouraging, but investors should be aware of the potential for future dilution.
Time to buy?
Aurora Cannabis has been making some impressive moves lately. Its turnaround strategy is starting to pay off, with a smart focus on high-margin medical cannabis and a push for better efficiency. The company has even managed to achieve positive free cash flow -- no small feat in this industry. Plus, their strong international presence and the bright outlook for global cannabis growth are points in the marijuana titan's favor.
But let's not get ahead of ourselves. The cannabis industry is still in its nascent stages, with regulations that can change at the drop of a hat. While Aurora's stock has seen some nice gains in 2024, it's worth remembering that it's taken quite a beating over the last several years (see graph below). Growing pains in the industry have been real, and Aurora hasn't been immune.
ACB data by YCharts.
What's the bottom line? If you're thinking about investing in Aurora Cannabis, you need to go in with your eyes wide open. This isn't a stock for the faint of heart -- it's for those who can handle stomach-churning volatility in the hunt for unusual growth opportunities.
Should you invest $1,000 in Aurora Cannabis right now?
Before you buy stock in Aurora Cannabis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Aurora Cannabis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $782,682!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
See the 10 stocks »
*Stock Advisor returns as of October 7, 2024
George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Is It Time to Load Up on Aurora Cannabis Stock?

Aurora Cannabis Inc. ACB has announced a research grant for the University of British Columbia (“UBC”) by Genome British Columbia (Genome BC), a not-for-profit organization supporting world-class genomics research and innovation in British Columbia. The collaborative project, titled “Genomics-enabled Aroma Breeding in Cannabis”, will directly support Aurora's genetics work and focus on validating genetic and chemical markers for fruity aroma in cannabis.
ACB Stock’s Trend Following the News
After the announcement, ACB shares fell 0.6% yesterday, closing at $5.37. Meanwhile, the latest collaboration with UBC underscores Aurora's dedication to innovation and scientific advancement in the cannabis sector. The genetics research aligns with its breeding goals and is set to enhance its breeding program with greater accuracy and efficiency on consumer-focused traits, driving future innovations. As a result, we anticipate that this development will positively boost market sentiment toward the stock.
The Canadian medical cannabis provider currently has a market capitalization of $297.2 million. In the last reported quarter, the company topped the Zacks Consensus Estimates for revenues and earnings by 20.2% and 68.6%, respectively. It delivered an earnings beat of 32.4%, on average, in the trailing four quarters.
More on Aurora Cannabis’ New Project
Aroma is a distinct characteristic of cannabis and an important aspect of consumer inclination. With this research, Aurora will advance beyond sensory analysis into validated aroma markers. Recently, the company patented a series of genetic and chemical markers for fruity aroma, identified through its CanD diversity panel. This collaboration will allow Aurora to validate these markers using cutting-edge approaches that would typically require significant funding. The insights gained from this work will support the discovery and launch of cultivars with unique and improved aromas, alongside high yield and potency.
Image Source: Zacks Investment Research
Aurora's in-kind contributions to the project include conducting sensory analysis of fruity aromas and leading bioinformatic analyses with in-house software. UBC, through Genome BC funding, will focus on sequencing transcriptomes, analyzing the volatile chemistry and conducting functional characterization of the genes responsible for fruity aromas in cannabis. If successful, the methods developed in this project will be adapted to explore other aromas and could strengthen Aurora's aroma-related intellectual property portfolio.
Industry Prospects Favoring ACB
A report from Grand View Research valued the global cannabis cultivation market at $392.1 billion in 2022 and is expected to witness a compound annual rate of 21.3% through 2030. Growing legalization and the adoption of cannabis for the treatment of chronic diseases are the key factors driving the growth. Several countries are easing the laws related to cannabis cultivation, especially for hemp cultivation, due to low THC content, which is increasing its adoption.
Other Developments in Aurora Cannabis
Earlier this month, ACB advanced research in auto-flowering technology — a genetic characteristic that automatically transitions the plant from the vegetative stage to the flowering stage rather than relying on changes in light cycles. The innovative work offers foundational insight into the flowering mechanism in cannabis, supporting future breeding strategies and potentially transforming outdoor cannabis cultivation in high-latitude regions, such as Canada.
ACB Stock Price Performance
Year to date, shares of Aurora Cannabis have risen 12.8%, the same as the industry.
ACB’s Zacks Rank and Key Picks
Aurora Cannabis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN and Phibro Animal Health PAHC, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have risen 63.9% in the past year. Estimates for the company’s earnings per share (EPS) have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 194.6% in the past year compared with the industry’s growth of 22.3%. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for Phibro Animal Health’s EPS have risen 0.7% in 2024 in the past 30 days. Shares of the company have rallied 72.7% in the past year compared with the industry’s 25.8% growth. PAHC’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 4.1%. In the last reported quarter, it delivered an earnings surprise of 20.6%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
AxoGen, Inc. (AXGN) : Free Stock Analysis Report
Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Aurora Cannabis Inc.

Sign up and unlock all the capabilities of the AI-screener